TITLE

The Influence of Haemoglobin A1c Levels on Platelet Aggregation and Platelet Turnover in Patients with Coronary Artery Disease Treated with Aspirin

AUTHOR(S)
Neergaard-Petersen, Søs; Hvas, Anne-Mette; Grove, Erik Lerkevang; Larsen, Sanne Bøjet; Gregersen, Søren; Kristensen, Steen Dalby
PUB. DATE
July 2015
SOURCE
PLoS ONE;7/6/2015, Vol. 10 Issue 7, p1
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Background: Hyperglycaemia may attenuate the antiplatelet effect of aspirin and thereby increase the risk of cardiovascular events. We investigated the influence of increased haemoglobin A1c (HbA1c) levels on platelet aggregation and turnover in a large cohort of patients with coronary artery disease (CAD) with type 2 diabetes, prediabetes or no diabetes. Methods: In this observational study, we included 865 stable CAD patients on 75 mg aspirin as mono-therapy of whom 242 patients had type 2 diabetes and were receiving antidiabetic drugs. Among 623 patients without diabetes, we classified 303 patients with prediabetes (HbA1c ≥5.7–6.4% [39–47 mmol/mol]) naive to antidiabetic drugs. Platelet aggregation was evaluated by the Multiplate Analyzer using arachidonic acid and collagen and by the VerifyNow Aspirin. Platelet turnover was evaluated by immature platelets using flow cytometry and platelet activation by soluble P-selectin. Results: CAD patients with type 2 diabetes had higher platelet aggregation (all p-values <0.01), platelet turnover (immature platelet count, p<0.01) and platelet activation (p<0.001) than patients without diabetes. CAD patients with prediabetes had increased platelet aggregation (p = 0.02) and platelet count (p = 0.02) compared with patients without diabetes. Increased levels of HbA1c correlated positively with increased platelet aggregation using arachidonic acid (r = 0.19, p<0.0001), collagen (r = 0.10, p<0.01) and VerifyNow (r = 0.15, p<0.0001), and with platelet count (r = 0.08, p = 0.01), immature platelet count (r = 0.11, p<0.001) and soluble P-selectin (r = 0.15, p<0.0001). These associations were mainly evident in non-diabetic and prediabetic CAD patients. Conclusions: CAD patients with prediabetes and diabetes may have attenuated antiplatelet effect of aspirin compared with CAD patients without diabetes. This may be related to increased platelet count in patients with prediabetes. Increased levels of HbA1c correlated positively, though weakly, with increased platelet aggregation, platelet turnover and platelet activation.
ACCESSION #
108629654

 

Related Articles

  • Pharmacogenetics and Clopidogrel Response in Patients Undergoing Percutaneous Coronary Interventions. Beitelshees, A. L.; Horenstein, R. B.; Vesely, M. R.; Mehra, M. R.; Shuldiner, A. R. // Clinical Pharmacology & Therapeutics;Mar2011, Vol. 89 Issue 3, p455 

    The article focuses on the association between cytochrome P450 2C19 (CYP2C19) and clopidogrel response in patients under percutaneous coronary interventions. It says that studies from 2008 show that CYP2C19*2 genotype increase the risk of patients to have cardiovascular events but the Platelet...

  • Triple antiplatelet therapy after PCI with aspirin, clopidogrel and cilostazol. Wilczynska, Patrycja; Smith, Andrew J. // Cardiology Today;Feb2010, Vol. 13 Issue 2, p28 

    The article discusses several studies on the safety and efficacy of triple antiplatelet therapy following percutaneous coronary intervention (PCI) with aspirin, clopidogrel and cilostazol.

  • Monitoring Aspirin and Clopidogrel Response: Testing Controversies and Recommendations. Karathanos, Athanasios; Geisler, Tobias // Molecular Diagnosis & Therapy;Jun2013, Vol. 17 Issue 3, p123 

    Antiplatelet therapy is the cornerstone of the treatment for patients with coronary artery disease (CAD). Dual therapy with clopidogrel and aspirin is currently the standard treatment after percutaneous coronary interventions. However, despite the use of clopidogrel, a considerable number of...

  • Triple versus Dual Antiplatelet Therapy in Acute Coronary Syndromes: Adding Cilostazol to Aspirin and Clopidogrel? Niazi, asfandyar K.; DiNicolantonio, James J.; Lavie, Carl J.; O'Keefe, James H.; Meier, Pascal; Bangalore, Sripal // Cardiology;Nov2013, Vol. 126 Issue 4, p233 

    Dual antiplatelet therapy (DAPT) with aspirin and a P2Y12 receptor antagonist is the standard of care in acute coronary syndromes. Additionally, novel P2Y12 receptor antagonists such as prasugrel and ticagrelor are even recommended over clopidogrel in certain clinical guidelines. Despite the...

  • Calprotectin and Platelet Aggregation in Patients with Stable Coronary Artery Disease. Larsen, Sanne Bøjet; Grove, Erik Lerkevang; Pareek, Manan; Kristensen, Steen Dalby; Hvas, Anne-Mette // PLoS ONE;May2015, Vol. 10 Issue 5, p1 

    Background: Recent studies suggest that the inflammation-associated protein calprotectin may be implicated in the pathogenesis of coronary artery disease (CAD). However, the impact of calprotectin levels on platelet aggregation in CAD patients has never been investigated. Objectives: We...

  • Cilostazol-Based Triple Antiplatelet Therapy Compared to Dual Antiplatelet Therapy in Patients with Coronary Stent Implantation: A Meta-Analysis of 5,821 Patients. Deng-feng Geng; Mo Liu; Dong-mei Jin; Wei Wu; Jing Deng; Jing-feng Wang // Cardiology;Sep2012, Vol. 122 Issue 3, p148 

    Background: Uncertainties still remain in terms of what kinds of patients benefit most from cilostazol-based triple antiplatelet therapy (TAT) after coronary stenting. Methods: We performed a meta-analysis of all relevant randomized controlled trials (RCTs) to investigate the effect of TAT...

  • Antiplatelet Therapy in Patients Undergoing Percutaneous Coronary Intervention: Economic Considerations. Weintraub, William S.; Mandel, Leonid; Weiss, Sandra A. // PharmacoEconomics;Nov2013, Vol. 31 Issue 11, p959 

    Percutaneous coronary intervention (PCI) is one of the most common medical procedures performed for treatment of coronary artery disease. Antiplatelet medications as adjunctive therapy for PCI are used routinely, with indications for specific agents or their combinations varying depending on the...

  • The relation between aspirin resistance and mean platelet volume in patients with significant coronary artery stenosis. Karaagac, Kemal; Ucar, Hakan; Karaagac, Esra; Yetgin, Zeynel Abidin; Akturk, Yusuf // HealthMed;2012, Vol. 6 Issue 11, p3701 

    Objective: Aspirin is the basis of antiplatelet treatment in patients with coronary artery disease, but aspirin resistance is seen in a wide range (0.4%- 83.3%) in these patients. Mean platelet volume (MPV) is a parameter of platelet activation. In this study, we aimed to investigate the...

  • Various drugs.  // Reactions Weekly;11/21/2009, Issue 1279, p33 

    The article describes the case of a 74-year-old man who developed thrombocytopenia while under a treatment regimen composed of clopidogrel, aspirin, paracetamol/chlorphenamine/caffeine and aminophenazone. The patient was diagnosed with coronary artery disease, and underwent a surgery for a...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics